Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 5/2000

01.10.2000 | Commentary

Role of BRCAgene dysfunction in breast and ovarian cancer predisposition

verfasst von: Ralph Scully

Erschienen in: Breast Cancer Research | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

Tumor suppressor genes that perform apparently generic cellular functions nonetheless cause tissue-specific syndromes in the human population when they are mutated in the germline. The two major hereditary breast/ovarian cancer predisposition genes, BRCA1 and BRCA2, appear to participate in a common pathway that is involved in the control of homologous recombination and in the maintenance of genomic integrity. How might such functions translate into the specific suppression of cancers of the breast and ovarian epithelia? Recent advances in the study of BRCA1 and BRCA2, discussed herein, have provided new opportunities to address this question.
Literatur
1.
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990, 250: 1684-1689.CrossRefPubMed
2.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed
3.
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994, 265: 2088-2090.CrossRefPubMed
4.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.CrossRefPubMed
5.
Smith SA, Easton DF, Evans DG, Ponder BA: Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet. 1992, 2: 128-131.CrossRefPubMed
6.
Neuhausen SL, Marshall CJ: Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 1994, 54: 6069-6072.PubMed
7.
Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF, et al: Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995, 10: 1673-1675.PubMed
8.
Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V, Barkardottir RB: Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res. 1995, 55: 4830-4832.PubMed
9.
Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al: BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994, 266: 120-122.CrossRefPubMed
10.
Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA: BRCA2 mutations in primary breast and ovarian cancers. Nature Genet. 1996, 13: 238-240.CrossRefPubMed
11.
12.
Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA: The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genet. 1995, 11: 17-26.CrossRefPubMed
13.
Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P: Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev . 1995, 9: 2712-2722.CrossRefPubMed
14.
Rajan JV, Marquis ST, Gardner HP, Chodosh LA: Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol . 1997, 184: 385-401. 10.1006/dbio.1997.8526.CrossRefPubMed
15.
Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH: Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nature Genet. 1996, 12: 191-194.CrossRefPubMed
16.
Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW: The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell. 1996, 85: 1009-1023. 10.1016/S0092-8674(00)81302-1.CrossRefPubMed
17.
Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature . 1997, 386: 804-810. 10.1038/386804a0.CrossRefPubMed
18.
Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashworth A: Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nature Genet. 1997, 17: 423-430.CrossRefPubMed
19.
Friedman LS, Thistlethwaite FC, Patel KJ, Yu VP, Lee H, Venkitaraman AR, Abel KJ, Carlton MB, Hunter SM, Colledge WH, Evans MJ, Ponder BA: Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 1998, 58: 1338-1343.PubMed
20.
Shen SX, Weaver Z, Xu X, Li C, Weinstein M, Chen L, Guan XY, Ried T, Deng CX: A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene. 1998, 17: 3115-3124. 10.1038/sj/onc/1202243.CrossRefPubMed
21.
Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX: Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell. 1999, 3: 389-395.CrossRefPubMed
22.
Cressman VL, Backlund DC, Avrutskaya AV, Leadon SA, Godfrey V, Koller BH: Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. Mol Cell Biol. 1999, 19: 7061-7075.CrossRefPubMedPubMedCentral
23.
Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, et al: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 1995, 11: 428-433.CrossRefPubMed
24.
Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genet. 1997, 15: 103-105.CrossRefPubMed
25.
The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999, 91: 1310-1316. 10.1093/jnci/91.15.1310.CrossRef
26.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral
27.
Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996, 77: 697-709. 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W.CrossRefPubMed
28.
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145. 10.1093/jnci/90.15.1138.CrossRefPubMed
29.
Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997, 88: 265-275.CrossRefPubMed
30.
Mizuta R, LaSalle JM, Cheng HL, Shinohara A, Ogawa H, Copeland N, Jenkins NA, Lalande M, Alt FW: RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci USA. 1997, 94: 6927-6932. 10.1073/pnas.94.13.6927.CrossRefPubMedPubMedCentral
31.
Lim DS, Hasty P: A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol. 1996, 16: 7133-7143.CrossRefPubMedPubMedCentral
32.
Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M, Matsushiro A, Yoshimura Y, Morita T: Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA. 1996, 93: 6236-6240. 10.1073/pnas.93.13.6236.CrossRefPubMedPubMedCentral
33.
Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell. 1998, 2: 317-328.CrossRefPubMed
34.
Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM: Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 1997, 90: 425-435.CrossRefPubMed
35.
Chen JJ, Silver D, Cantor S, Livingston DM, Scully R: BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 1999, 59 (7 suppl): 1752s-1756s.
36.
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH: Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 1999, 285: 747-750. 10.1126/science.285.5428.747.CrossRefPubMed
37.
Patel KJ, Vu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR: Involvement of Brca2 in DNA repair. Mol Cell. 1998, 1: 347-357.CrossRefPubMed
38.
Moynahan ME, Chiu JW, Koller BH, Jasin M: Brca1 controls homology-directed DNA repair. Mol Cell. 1999, 4: 511-518.CrossRefPubMed
39.
Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, Koller BH: BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene. 1999, 18: 7900-7907. 10.1038/sj/onc/1203334.CrossRefPubMed
40.
Foray N, Randrianarison V, Marot D, Perricaudet M, Lenoir G, Feunteun J: Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene. 1999, 18: 7334-7342. 10.1038/sj/onc/1203165.CrossRefPubMed
41.
Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM: Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell. 1999, 4: 1093-1099.CrossRefPubMed
42.
Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA: BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science. 1998, 281: 1009-1012. 10.1126/science.281.5379.1009.CrossRefPubMed
43.
Tutt A, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A: Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol. 1999, 9: 1107-1110. 10.1016/S0960-9822(99)80479-5.CrossRefPubMed
44.
Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW: Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 1997, 11: 1242-1252.CrossRefPubMed
45.
Hakem R, de la Pompa Jl, Elia A, Potter J, Mak TW: Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nature Genet. 1997, 16: 298-302.CrossRefPubMed
46.
Lee H, Trainer AH, Friedman LS, Thistlethwaite FC, Evans MJ, Ponder BA, Venkitaraman AR: Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell. 1999, 4: 1-10.CrossRefPubMed
47.
Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX: Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genet. 1999, 22: 37-43. 10.1038/8743.CrossRefPubMed
48.
Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller BH: Mammary tumor formation in p53- and BRCA1-deficient mice. Cell Growth Differ. 1999, 10: 1-10.PubMed
49.
Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA: p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene. 1998, 17: 1681-1689. 10.1038/sj/onc/1202106.CrossRefPubMed
50.
Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ, Crook T: Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene. 1999, 18: 2451-2459. 10.1038/sj/onc/1202565.CrossRefPubMed
51.
Kordon EC, Smith GH: An entire functional mammary gland may comprise the progeny from a single cell. Development. 1998, 125: 1921-1930.PubMed
52.
Chepko G, Smith GH: Mammary epithelial stem cells: our current understanding. J Mammary Gland Biol Neoplasia. 1999, 4: 35-52. 10.1023/A:1018752519356.CrossRefPubMed
53.
Tsai YC, Lu Y, Nichols PW, Zlotnikov G, Jones PA, Smith HS: Contiguous patches of normal human mammary epithelium derived from a single stem cell: implications for breast carcinogenesis. Cancer Res. 1996, 56: 402-404.PubMed
54.
Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS: Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 1998, 16: 536-544.PubMed
55.
Tokunaga M, Norman JE, Asano M, Tokuoka S, Ezaki H, Nishimori I, Tsuji Y: Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74. J Natl Cancer Inst. 1979, 62: 1347-1359.PubMed
56.
Tokunaga M, Land CE, Yamamoto T, Asano M, Tokuoka S, Ezaki H, Nishimori I: Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat Res. 1987, 112: 243-272.CrossRefPubMed
57.
Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S: Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res. 1994, 138: 209-223.CrossRefPubMed
58.
Land CE: Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. JAMA. 1995, 274: 402-407. 10.1001/jama.274.5.402.CrossRefPubMed
59.
Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, Stratton MR, O'Hare MJ: Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol. 1999, 189: 496-503. 10.1002/(SICI)1096-9896(199912)189:4<496::AID-PATH485>3.0.CO;2-D.CrossRefPubMed
60.
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995, 268: 1336-1338.CrossRefPubMed
61.
62.
Liehr JG, Avitts TA, Randerath E, Randerath K: Estrogen-induced endogenous DNA adduction: possible mechanism of hormonal cancer. Proc Natl Acad Sci USA. 1986, 83: 5301-5305.CrossRefPubMedPubMedCentral
63.
Fishman J, Osborne MP, Telang NT: The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci. 1995, 768: 91-100.CrossRefPubMed
64.
Cox MM, Goodman MF, Kreuzer KN, Sherratt DJ, Sandler SJ, Marians KJ: The importance of repairing stalled replication forks. Nature. 2000, 404: 37-41. 10.1016/S0014-5793(97)00080-X.CrossRefPubMed
65.
66.
Martin FL, Venitt S, Carmichael PL, Crofton-Sleigh C, Stone EM, Cole KJ, Gusterson BA, Grover PL, Phillips DH: DNA damage in breast epithelial cells: detection by the single-cell gel (comet) assay and induction by human mammary lipid extracts. Carcinogenesis. 1997, 18: 2299-2305. 10.1093/carcin/18.12.2299.CrossRefPubMed
67.
Chapman MS, Verma IM: Transcriptional activation by BRCA1. Nature. 1996, 382: 678-679. 10.1038/382678a0.CrossRefPubMed
68.
Monteiro AN, August A, Hanafusa H: Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA. 1996, 93: 13595-13599. 10.1073/pnas.93.24.13595.CrossRefPubMedPubMedCentral
69.
Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T: Transcriptional activation functions in BRCA2. Nature . 1997, 386: 772-773. 10.1038/386772a0.CrossRefPubMed
70.
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD: BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA. 1997, 94: 5605-5610. 10.1073/pnas.94.11.5605.CrossRefPubMedPubMedCentral
71.
Siddique H, Zou JP, Rao VN, Reddy ES: The BRCA2 is a histone acetyltransferase. Oncogene. 1998, 16: 2283-2285. 10.1038/sj/onc/1202003.CrossRefPubMed
72.
Fuks F, Milner J, Kouzarides T: BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene. 1998, 17: 2531-2534. 10.1038/sj/onc/1202475.CrossRefPubMed
73.
Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R: The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem. 1998, 273: 25388-25392. 10.1074/jbc.273.39.25388.CrossRefPubMed
74.
Yarden RI, Brody LC: BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA. 1999, 96: 4983-4988. 10.1073/pnas.96.9.4983.CrossRefPubMedPubMedCentral
75.
Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM: CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA. 2000, 97: 1020-1025. 10.1073/pnas.97.3.1020.CrossRefPubMedPubMedCentral
76.
Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL, El-Deiry WS: Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature. 1997, 389: 187-190. 10.1038/38291.CrossRefPubMed
77.
Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA: Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999, 97: 575-586. 10.1016/S0092-8674(00)80769-2.CrossRefPubMed
78.
MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, Muschel RJ, Cowan KH, El-Deiry WS: BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem. 2000, 275: 2777-2785. 10.1074/jbc.275.4.2777.CrossRefPubMed
79.
Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H: BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA . 1998, 95: 2302-2306. 10.1073/pnas.95.5.2302.CrossRefPubMedPubMedCentral
80.
Marmorstein LY, Ouchi T, Aaronson SA: The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA. 1998, 95: 13869-13874. 10.1073/pnas.95.23.13869.CrossRefPubMedPubMedCentral
81.
Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 1998, 16: 1713-1721. 10.1038/sj/onc/1201932.CrossRefPubMed
82.
Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ, Calzone FJ: Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene. 1997, 14: 1-16. 10.1038/sj/onc/1200924.CrossRefPubMed
83.
Somasundaram K, MacLachlan TK, Burns TF, Sgagias M, Cowan KH, Weber BL, el-Deiry WS: BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene. 1999, 18: 6605-6614. 10.1038/sj/onc/1203284.CrossRefPubMed
84.
Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999, 284: 1354-1356. 10.1126/science.284.5418.1354.CrossRefPubMed
Metadaten
Titel
Role of BRCAgene dysfunction in breast and ovarian cancer predisposition
verfasst von
Ralph Scully
Publikationsdatum
01.10.2000
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2000
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr76

Weitere Artikel der Ausgabe 5/2000

Breast Cancer Research 5/2000 Zur Ausgabe

Research article

Polymorphic repeat in AIB1 does not alter breast cancer risk

Review

Estrogen receptor transcription and transactivation Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors

Commentary

Nontransgenic models of breast cancer

Review

Estrogen receptor transcription and transactivation Basic aspects of estrogen action

Commentary

Metastases: the glycan connection

Review

Estrogen receptor transcription and transactivation Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise